ACTEMRA® (tocilizumab) is a prescription medicine for patients 2 years and older with active polyarticular juvenile idiopathic arthritis (PJIA). It is thought to work by blocking the IL-6 receptor, a key messenger that is believed to cause the immune system to attack the healthy cells which can contribute to the signs and symptoms of PJIA.
ACTEMRA can be given by IV infusion or SC injection. The dosing guidelines differ by weight: for IV, children <30 kg receive 10 mg/kg every 4 weeks, and ≥30 kg receive 8 mg/kg every 4 weeks. For SC injection, <30 kg is 162 mg every 3 weeks; ≥30 kg is 162 mg every 2 weeks.
Common side effects include sinus infections, headache, higher blood pressure, and injection-site reactions. Serious risks include serious infections, gastrointestinal perforation, liver injury, hematologic abnormalities, and hypersensitivity. Monitoring includes complete blood count (CBC), aspartate aminotransferase/alanine Aminotransferase (AST/ALT), and lipids at regular intervals; latent TB and hepatitis screening prior to initiation. Call your child’s healthcare provider if your child develops fever, chills, or other concerning symptoms. Do not take ACTEMRA if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA.